

#UnitedAgainstCoronavirus

#StrongerTogether | #GlobalResponse

ACT ACCELERATOR TX PILLAR

July 2020

A global crisis that is far from over...

The health crisis has evolved into a severe socio economic issue



Global deaths to date



Weekly increase in global cases



GDP loss per month

...calling for a global accelerated response

A coordinated action...

At global scale...


Faster...

At low risk...

If a ~\$7B investment in ACT-A Tx accelerates access to health products by just **one week** the GDP loss avoided would **pay back the investment 10 times over**

Defeating the health crisis requires a comprehensive approach

We need a **full arsenal** to combat this pandemic disease



Therapeutics are more than a stop-gap measure, they are **long-term solutions**

- Enable **Test & Treat** rather than Test/Track/Isolate
- Essential to saving lives and preventing disease progression across **all stages of disease**
- **Critical coverage** before vaccines are fully scaled and while safety /efficacy questions remain
- Complement vaccines to **provide protection to all target populations**


WHAT'S OUR PLAN ON THERAPEUTICS?

3 Objectives



R&D

Discover fast



MARKET
PREPAREDNESS

Produce at scale




PROCUREMENT
DEPLOYMENT

Deliver to all


Therapeutics Partnership is **ready to work**

ACT–Accelerator



We are evaluating a wide range of candidates to deploy safe and effective Tx at-scale

Two waves of candidates expected



Therapies targeted against different use cases along stages of disease progression

Use case	Prevent infection	Prevent severity	Prevent death
PrEP Pre-exposure prophylaxis	✓		
PEP Post-exposure prophylaxis	✓		
Mild	✓	✓	
Moderate		✓	
Severe & Critical			✓

What have we achieved so far?

1

**Monitored 1,700 clinical trials
~200 actionable readouts
25-30 priority assets**

2

**Invested \$175M+ to address
critical Research &
Development needs**

3

**Developed Target Product
Profiles to guide therapeutic
development**

4

**Developed tools and approach
to be ready to make
anticipated investments**


5

**Identify interventions for
affordability, access and
regulatory for priority assets**


6

**Secured add. supply of
Dexamethasone for LMICs in
less than 20 days to cover 25-
50% needs**

Novel and simple therapies pursued in parallel



Based on preliminary matrix placement, identified priorities by asset for each workstream



Implications

WS1

Consider focus on accelerating confirmation of anticipated high health impact of **novel antivirals and mAbs**, pending no overlap in funding efforts

Consider accelerating evidence generation of repurposed **antiviral combinations** to improve health impact score

WS2

Focus at-risk market preparedness on **mAbs and novel small molecules**

WS3

Focus on procurement of **Dexamethasone**

Note: Initial X-axis (scaling ability) denoted High-Medium-Low; WS2 to conduct detailed analysis on promising candidates

What are the challenges in the next 6 months?



Discover fast

R&D

Next challenges within 6 months

- **Fund preclinical study and Ph1/2/3** for repurposed antivirals and combination regimens
- **Fund R&D for antibody and novel antivirals** as needed (based on ongoing industry efforts)


How much we need in the next 6 month

US\$1B

Lead / recipients



BILL & MELINDA GATES foundation



Produce at scale

Market Preparedness

- **Reserve sufficient and affordable manufacturing capacity for and scale up manufacturing and proceed with early market interventions** for
 - 2 monoclonal antibody treatments
 - at least 1 small molecule treatment

US\$0.3Bn

Unitaid
Innovation in Global Health



Deliver to all

Procurement and deployment

- Perform **rapid response procurement** of at least 1 existing repurposed treatment
- **Supply** of treatments for mild and moderate cases
- Collaborative procedures for regulatory in countries, allocation framework

US\$2.5Bn

The Global Fund
To Fight AIDS, Tuberculosis and Malaria



The roadmap is clear. But nothing can be done without investments.

Within 3 months



Within 6 months



Within 12 months



WHY OUR APPROACH ON THERAPEUTICS MAKES A DIFFERENCE

Our assets to maximize impact

MEANS



A coordinated, global approach



A trusted leadership with experienced partners and WHO support



Risk-mitigated approach by pursuing a large portfolio of therapeutic solutions



Pioneer new development processes by parallelizing workstreams from R&D to delivery

BENEFITS

De-risked investment

Maximizing chances of bringing a full set of safe and effective therapeutics for every population and use case

No country alone could finance an R&D pipeline on such a large scale

Faster solutions at scale

Accelerating the path from breakthrough to delivery


Equitable solutions

Working towards access for all populations, to allow every economy to restart



Therapeutics are our
opportunity to accelerate the
end of the pandemic now,
together.

Investing in ACT-A Therapeutics
is investing in confidence.



#UnitedAgainstCoronavirus
#StrongerTogether | #GlobalResponse